|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heintz AP: Surgery in advanced ovarian
carcinoma: Is there proof to show the benefit? Eur J Surg Oncol.
14:91–99. 1988.PubMed/NCBI
|
|
3
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno
T, Machida S and Sato I: A feasibility study of paclitaxel and
carboplatin therapy in Japanese patients with epithelial ovarian
cancer. Oncol Rep. 10:951–955. 2003.PubMed/NCBI
|
|
5
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fahmy RG, Dass CR, Sun LQ, Chesterman CN
and Khachigian LM: Transcription factor Egr-1 supports
FGF-dependent angiogenesis during neovascularization and tumor
growth. Nat Med. 9:1026–1032. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Reilly MS, Holmgren L, Shing Y, Chen C,
Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J:
Angiostatin: A novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell.
79:315–328. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dawson DW, Volpert OV, Gillis P, Crawford
SE, Xu H, Benedict W and Bouck NP: Pigment epithelium-derived
factor: A potent inhibitor of angiogenesis. Science. 285:245–248.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clapp C, Martial JA, Guzman RC,
Rentier-Delure F and Weiner RI: The 16-kilodalton N-terminal
fragment of human prolactin is a potent inhibitor of angiogenesis.
Endocrinology. 133:1292–1299. 1993.PubMed/NCBI
|
|
12
|
Tolsma SS, Volpert OV, Good DJ, Frazier
WA, Polverini PJ and Bouck N: Peptides derived from two separate
domains of the matrix protein thrombospondin-1 have anti-angiogenic
activity. J Cell Biol. 122:497–511. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watanabe K, Hasegawa Y, Yamashita H,
Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al:
Vasohibin as an endothelium-derived negative feedback regulator of
angiogenesis. J Clin Invest. 114:898–907. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimizu K, Watanabe K, Yamashita H, Abe M,
Yoshimatsu H, Ohta H, Sonoda H and Sato Y: Gene regulation of a
novel angiogenesis inhibitor, vasohibin, in endothelial cells.
Biochem Biophys Res Commun. 327:700–706. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heishi T, Hosaka T, Suzuki Y, Miyashita H,
Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T,
et al: Endogenous angiogenesis inhibitor vasohibin1 exhibits
broad-spectrum anti-lymphangiogenic activity and suppresses lymph
node metastasis. Am J Pathol. 176:1950–1958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki Y, Kobayashi M, Miyashita H, Ohta
H, Sonoda H and Sato Y: Isolation of a small vasohibin-binding
protein (SVBP) and its role in vasohibin secretion. J Cell Sci.
123:3094–3101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hosaka T, Kimura H, Heishi T, Suzuki Y,
Miyashita H, Ohta H, Sonoda H, Moriya T, Suzuki S, Kondo T, et al:
Vasohibin-1 expression in endothelium of tumor blood vessels
regulates angiogenesis. Am J Pathol. 175:430–439. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshinaga K, Ito K, Moriya T, Nagase S,
Takano T, Niikura H, Yaegashi N and Sato Y: Expression of vasohibin
as a novel endothelium-derived angiogenesis inhibitor in
endometrial cancer. Cancer Sci. 99:914–919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshinaga K, Ito K, Moriya T, Nagase S,
Takano T, Niikura H, Sasano H, Yaegashi N and Sato Y: Roles of
intrinsic angiogenesis inhibitor, vasohibin, in cervical
carcinomas. Cancer Sci. 102:446–451. 2011. View Article : Google Scholar
|
|
20
|
Tamaki K, Moriya T, Sato Y, Ishida T,
Maruo Y, Yoshinaga K, Ohuchi N and Sasano H: Vasohibin-1 in human
breast carcinoma: A potential negative feedback regulator of
angiogenesis. Cancer Sci. 100:88–94. 2009. View Article : Google Scholar
|
|
21
|
Tamaki K, Sasano H, Maruo Y, Takahashi Y,
Miyashita M, Moriya T, Sato Y, Hirakawa H, Tamaki N, Watanabe M, et
al: Vasohibin-1 as a potential predictor of aggressive behavior of
ductal carcinoma in situ of the breast. Cancer Sci. 101:1051–1058.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita H, Abe M, Watanabe K, Shimizu K,
Moriya T, Sato A, Satomi S, Ohta H, Sonoda H and Sato Y: Vasohibin
prevents arterial neointimal formation through angiogenesis
inhibition. Biochem Biophys Res Commun. 345:919–925. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sato H, Abe T, Wakusawa R, Asai N,
Kunikata H, Ohta H, Sonoda H, Sato Y and Nishida K: Vitreous levels
of vasohibin-1 and vascular endothelial growth factor in patients
with proliferative diabetic retinopathy. Diabetologia. 52:359–361.
2009. View Article : Google Scholar
|
|
24
|
Nasu T, Maeshima Y, Kinomura M,
Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, Sonoda H, Sato Y and
Makino H: Vasohibin-1, a negative feedback regulator of
angiogenesis, ameliorates renal alterations in a mouse model of
diabetic nephropathy. Diabetes. 58:2365–2375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saito D, Maeshima Y, Nasu T, Yamasaki H,
Tanabe K, Sugiyama H, Sonoda H, Sato Y and Makino H: Amelioration
of renal alterations in obese type 2 diabetic mice by vasohibin-1,
a negative feedback regulator of angiogenesis. Am J Physiol Renal
Physiol. 300:F873–F886. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wakusawa R, Abe T, Sato H, Yoshida M,
Kunikata H, Sato Y and Nishida K: Expression of vasohibin, an
antiangiogenic factor, in human choroidal neovascular membranes. Am
J Ophthalmol. 146:235–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wakusawa R, Abe T, Sato H, Sonoda H, Sato
M, Mitsuda Y, Takakura T, Fukushima T, Onami H, Nagai N, et al:
Suppression of choroidal neovascularization by vasohibin-1, a
vascular endothelium-derived angiogenic inhibitor. Invest
Ophthalmol Vis Sci. 52:3272–3280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fogh J, Wright WC and Loveless JD: Absence
of HeLa cell contamination in 169 cell lines derived from human
tumors. J Natl Cancer Inst. 58:209–214. 1977.PubMed/NCBI
|
|
29
|
Mesiano S, Ferrara N and Jaffe RB: Role of
vascular endothelial growth factor in ovarian cancer: Inhibition of
ascites formation by immunoneutralization. Am J Pathol.
153:1249–1256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wiener JR, Nakano K, Kruzelock RP, Bucana
CD, Bast RC Jr and Gallick GE: Decreased Src tyrosine kinase
activity inhibits malignant human ovarian cancer tumor growth in a
nude mouse model. Clin Cancer Res. 5:2164–2170. 1999.PubMed/NCBI
|
|
31
|
Urabe M, Hasumi Y, Ogasawara Y, Matsushita
T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K and Ozawa
K: A novel dicistronic AAV vector using a short IRES segment
derived from hepatitis C virus genome. Gene. 200:157–162. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al; Gynecologic Oncology Group. Incorporation of bevacizumab in
the primary treatment of ovarian cancer. N Engl J Med.
365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al; ICON7 Investigators. A phase 3
trial of bevacizumab in ovarian cancer. N Engl J Med.
365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aghajanian C, Blank SV, Goff BA, Judson
PL, Teneriello MG, Husain A, Sovak MA, Yi J and Nycum LR: OCEANS: A
randomized, double-blind, placebo-controlled phase III trial of
chemotherapy with or without bevacizumab in patients with
platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Casanovas O, Hicklin DJ, Bergers G and
Hanahan D: Drug resistance by evasion of antiangiogenic targeting
of VEGF signaling in late-stage pancreatic islet tumors. Cancer
Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Batchelor TT, Sorensen AG, di Tomaso E,
Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M,
et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor,
normalizes tumor vasculature and alleviates edema in glioblastoma
patients. Cancer Cell. 11:83–95. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen J, Yang X, Xiao WH, Hackett SF, Sato
Y and Campochiaro PA: Vasohibin is up-regulated by VEGF in the
retina and suppresses VEGF receptor 2 and retinal
neovascularization. FASEB J. 20:723–725. 2006.PubMed/NCBI
|
|
39
|
Zhou SY, Xie ZL, Xiao O, Yang XR, Heng BC
and Sato Y: Inhibition of mouse alkali burn induced-corneal
neovascularization by recombinant adenovirus encoding human
vasohibin-1. Mol Vis. 16:1389–1398. 2010.PubMed/NCBI
|
|
40
|
Takei Y, Mizukami H, Saga Y, Yoshimura I,
Hasumi Y, Takayama T, Kohno T, Matsushita T, Okada T, Kume A, et
al: Suppression of ovarian cancer by muscle-mediated expression of
soluble VEGFR-1/Flt-1 using adeno-associated virus serotype
1-derived vector. Int J Cancer. 120:278–284. 2007. View Article : Google Scholar
|
|
41
|
Takahashi K, Mizukami H, Saga Y, Takei Y,
Urabe M, Kume A, Machida S, Fujiwara H, Suzuki M and Ozawa K:
Suppression of lymph node and lung metastases of endometrial cancer
by muscle-mediated expression of soluble vascular endothelial
growth factor receptor-3. Cancer Sci. 104:1107–1111. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mueller C and Flotte TR: Clinical gene
therapy using recombinant adeno-associated virus vectors. Gene
Ther. 15:858–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miyashita H, Watanabe T, Hayashi H, Suzuki
Y, Nakamura T, Ito S, Ono M, Hoshikawa Y, Okada Y, Kondo T, et al:
Angiogenesis inhibitor vasohibin-1 enhances stress resistance of
endothelial cells via induction of SOD2 and SIRT1. PLoS One.
7:e464592012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyashita H, Suzuki H, Ohkuchi A and Sato
Y: Mutual balance between vasohibin-1 and soluble VEGFR-1 in
endothelial cells. Pharmaceuticals. 4:782–793. 2011. View Article : Google Scholar
|
|
45
|
Li D, Zhou K, Wang S, Shi Z and Yang Z:
Recombinant adeno-virus encoding vasohibin prevents tumor
angiogenesis and inhibits tumor growth. Cancer Sci. 101:448–452.
2010. View Article : Google Scholar
|
